A Phase 2 interventional study of Daratumumab in Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Follicular, sponsored by Janssen Research & Development, LLC. Terminated at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Mantle-Cell · Johnson & Johnson.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2015, is one of 4 in phase 2, and was the 9th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →None of the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 48 across the 12 interventional studies, 54 across the 3 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Lymphoma, Mantle-Cell by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess overall response rate [ORR, including complete response (CR) and partial response (PR)], of daratumumab in participants with non-Hodgkin's lymphoma [a cancer of the lymph nodes (or tissues)-NHL] and to evaluate association between ORR and CD38 expression level in order to determine a threshold for CD38 expression level in each NHL subtype, above which daratumumab activity is enhanced in participants with relapsed or refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
This is an open label (everyone knows the study intervention), Phase 2 study to evaluate efficacy and safety of daratumumab in relapsed or refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. The study will have three phases. Screening phase, treatment phase, follow-up phase. Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion approximately 3.5 years. Participants will primarily be assessed for overall response rate. Safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Drug: Daratumumab
Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), or Magnetic resonance imaging (MRI) scans where applicable. CR is defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
Time frame: After the first dose until disease progression, withdrawal of consent from study participation, or the end of study (approximately 1.9 years)
Duration of Response
Duration of response was the duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD). PD is defined as any new lesion \>1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50% increase in previously involved sites.
Time frame: Approximately 1.9 years
Progression Free Survival (PFS)
PFS was defined as the duration from the date of the first daratumumab dose to the date of progression or death, whichever comes first.
Time frame: Approximately 1.9 years
Overall Survival (OS)
Overall survival was defined as the duration from the date of the first daratumumab dose to the date of death.
Time frame: Approximately 1.9 years
Time to Response
Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR) is first documented.
Time frame: Approximately 1.9 years
| Milestone | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| Started | 15 | 16 | 5 |
| Completed | 0 | 0 | 0 |
| Not completed | 15 | 16 | 5 |
| Withdrew: Death | 11 | 3 | 4 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 13 | 1 |
ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), or Magnetic resonance imaging (MRI) scans where applicable. CR is defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
| Percentage of participants | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| Overall Response Rate (ORR) | 6.7 (0.2 to 31.9) | 12.5 (1.6 to 38.3) | 0 (NA to NA) |
Duration of response was the duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD). PD is defined as any new lesion \>1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50% increase in previously involved sites.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| Participant 1 | 1.6 | 0.7 | — |
| Participant 2 | NA | 7.4 | — |
PFS was defined as the duration from the date of the first daratumumab dose to the date of progression or death, whichever comes first.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| Progression Free Survival (PFS) | 1.2 (0.6 to 1.7) | 3.3 (1.9 to 3.8) | 1.3 (0.5 to 1.9) |
Overall survival was defined as the duration from the date of the first daratumumab dose to the date of death.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| Overall Survival (OS) | 4.9 (2.1 to 9.0) | 17.2 (15.0 to NA) | 4.8 (1.7 to NA) |
Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR) is first documented.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| Participant 1 | 1.9 | 2.3 | — |
| Participant 2 | NA | 1.9 | — |
Collected over Up to 1.9 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma (DLBCL) | 11/15 (73.3%) | 6/15 (40%) | 15/15 (100%) |
| Follicular Lymphoma (FL) | 3/16 (18.8%) | 6/16 (37.5%) | 16/16 (100%) |
| Mantle Cell Lymphoma (MCL) | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| Event | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/15 | 0/16 | 2/5 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/15 | 1/16 | 1/5 |
| General Physical Health DeteriorationGeneral disorders | 1/15 | 0/16 | 1/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/15 | 0/16 | 0/5 |
| Abdominal Pain LowerGastrointestinal disorders | 1/15 | 0/16 | 0/5 |
| PneumoniaInfections and infestations | 1/15 | 1/16 | 0/5 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/15 | 0/16 | 0/5 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 1/15 | 0/16 | 0/5 |
| Acute Kidney InjuryRenal and urinary disorders | 1/15 | 0/16 | 0/5 |
| Chronic Kidney DiseaseRenal and urinary disorders | 1/15 | 0/16 | 0/5 |
| Event | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 7/15 | 6/16 | 4/5 |
| NauseaGastrointestinal disorders | 5/15 | 1/16 | 2/5 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 0/15 | 1/16 | 2/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/15 | 2/16 | 2/5 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 0/15 | 2/16 | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 1/15 | 5/16 | 1/5 |
| Abdominal PainGastrointestinal disorders | 2/15 | 5/16 | 1/5 |
| HeadacheNervous system disorders | 0/15 | 5/16 | 1/5 |
| VomitingGastrointestinal disorders | 4/15 | 0/16 | 1/5 |
| FatigueGeneral disorders | 4/15 | 3/16 | 1/5 |
| Age, Categorical(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 9 | 4 | 18 |
| >=65 years | 10 | 7 | 1 | 18 |
| Age, Continuous(years) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| Mean | 66.7 ± 11.88 | 62.3 ± 9.77 | 59.8 ± 6.69 | 63.8 ± 10.45 |
| Sex: Female, Male(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| Female | 6 | 5 | 0 | 11 |
| Male | 9 | 11 | 5 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 12 | 15 | 2 | 29 |
| Unknown or Not Reported | 3 | 0 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| Asian | 4 | 2 | 0 | 6 |
| White | 7 | 13 | 2 | 22 |
| Unknown | 1 | 0 | 0 | 1 |
| Not Reported | 3 | 1 | 1 | 5 |
| Other | 0 | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| Australia | 0 | 2 | 0 | 2 |
| Belgium | 2 | 0 | 0 | 2 |
| France | 4 | 2 | 0 | 6 |
| Netherlands | 2 | 3 | 2 | 7 |
| Republic of Korea | 4 | 2 | 0 | 6 |
| Turkey | 2 | 2 | 1 | 5 |
| United States | 1 | 5 | 2 | 8 |
| CD38 expression value(Percentage of CD38 expression) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Mantle Cell Lymphoma (MCL) | Total |
|---|---|---|---|---|
| Mean | 76.3 ± 18.07 | 70.3 ± 16.78 | 64 ± 8.22 | 71.9 ± 16.66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Jun 2017, 20 months.
Results were first posted in Jun 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →